Liu showed that by downregulating HMGB1 levels and inhibiting NF-κBp65 phosphorylation, the drug was able to improve the diabetes-induced reductions in diastolic and systolic cardiac systolic function and conduction abnormalities and alleviate cardiac insufficiency in diabetic heart disease (50). Here, HMGB1 is linked to heart failure.